ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2421

Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2154

Whole-Body MRI Findings in a Cohort of Children with Chronic Nonbacterial Osteomyelitis

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2086

WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2253

Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:45AM-11:00AM: Abstract Number: 1731

A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System

Abstracts: Immunological Complications of Medical Therapy (1728–1733)

10:45AM-11:00AM: Abstract Number: 1743

Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis

Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)

10:45AM-11:00AM: Abstract Number: 1737

CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype

Abstracts: Osteoarthritis & Joint Biology – Basic Science (1734–1739)

10:45AM-11:00AM: Abstract Number: 1749

External validation of a combined clinical and genetic risk score for the identification of interstitial lung disease in rheumatoid arthritis

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

10:45AM-11:00AM: Abstract Number: 1767

Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis

Abstracts: Vasculitis – ANCA-Associated (1764–1769)

10:45AM-11:00AM: Abstract Number: 1755

Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

10:45AM-11:00AM: Abstract Number: 1761

The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies

Abstracts: Systemic Lupus Erythematosus – Animal Models (1758–1763)

11:00AM-11:15AM: Abstract Number: 1738

Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes

Abstracts: Osteoarthritis & Joint Biology – Basic Science (1734–1739)

11:00AM-11:15AM: Abstract Number: 1756

Exosomal Cargo and Surface Markers: Informative Signals in Axial Spondyloarthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

11:00AM-11:15AM: Abstract Number: 1732

Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis

Abstracts: Immunological Complications of Medical Therapy (1728–1733)

11:00AM-11:15AM: Abstract Number: 1744

Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus

Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].